Global Quetiapine Fumarate Market Growth 2023-2029

Global Quetiapine Fumarate Market Growth 2023-2029

Quetiapine Fumarate is an atypical antipsychotic drug used to treat psychiatric disorders such as schizophrenia, bipolar disorder and depression. It may be used alone or in combination with other psychiatric medications. It is taken orally, and is available only by prescription, under the supervision of a medical practitioner.

LPI (LP Information)' newest research report, the “Quetiapine Fumarate Industry Forecast” looks at past sales and reviews total world Quetiapine Fumarate sales in 2022, providing a comprehensive analysis by region and market sector of projected Quetiapine Fumarate sales for 2023 through 2029. With Quetiapine Fumarate sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Quetiapine Fumarate industry.

This Insight Report provides a comprehensive analysis of the global Quetiapine Fumarate landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Quetiapine Fumarate portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Quetiapine Fumarate market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Quetiapine Fumarate and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Quetiapine Fumarate.

The global Quetiapine Fumarate market size is projected to grow from US$ 156.2 million in 2022 to US$ 132.9 million in 2029; it is expected to grow at a CAGR of 132.9 from 2023 to 2029.

Europe is the largest Quetiapine Fumarate market with about 92% market share. China is follower, accounting for about 2% market share.

The key players are AstraZeneca, Intas, TAPI, Accord, Hexal, Dr.Reddy's, Lupin, Sun Pharmaceutical, Hunan Dongting Pharm, SuZhou NO.4 Phamaceutical Factory, Fuan Pharmaceutical, Zhejiang Supor Pharmaceuticals, Zhejiang Huahai Pharmaceutical etc. Top 3 companies occupied about 74% market share.

This report presents a comprehensive overview, market shares, and growth opportunities of Quetiapine Fumarate market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Immediate Release Tablets

Extended Release Tablets

Segmentation by application

Adult

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

AstraZeneca

Intas

TAPI

Accord

Hexal

Dr.Reddy's

Lupin

Sun Pharmaceutical

Hunan Dongting Pharm

SuZhou NO.4 Phamaceutical Factory

Fuan Pharmaceutical

Zhejiang Supor Pharmaceuticals

Zhejiang Huahai Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Quetiapine Fumarate market?

What factors are driving Quetiapine Fumarate market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Quetiapine Fumarate market opportunities vary by end market size?

How does Quetiapine Fumarate break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.